Enzo Biochem, Inc. (NYSE:ENZ), a biotechnology company specializing in
gene identification and genetic and immune regulation technologies for
diagnostic and therapeutic applications and laboratory services,
announced today that its subsidiary, Enzo Life Sciences, Inc., has been
granted a new patent by the U.S. Patent and Trademark Office that will
complement existing proprietary technologies that have applications in
the molecular diagnostics and life sciences marketplaces.
"The addition of this patent to our growing intellectual property
portfolio adds to the growing line of products and technology we are
providing to the medical research establishment worldwide,” said Elazar
Rabbani, Ph.D., Chairman and CEO, and the lead inventor on the patent.
"These patents have applications that can potentially enhance the
visualization of minute quantities of biological material, which in
turn, can lead to more sensitive diagnostic assays.”
Patent #7,514,551 entitled "Multisignal Labeling Reagents and
Processes and
Uses Therefor”, covers the use of labeled
nucleotides that when linked to other biological molecules such as
proteins, provide enhanced signals and solubility, thus rendering them
more readily detectable. Such technology can have wide ranging uses in
the development of next generation of diagnostic kits, where the
detection of a virus or a bacteria, for example, can be more sensitively
performed.
The Company, led by its founder Dr. Rabbani, has over 300 patents and
patent applications throughout the world. These inventions have
application in numerous and diverse fields and diagnostic technologies,
including nucleic acid modification, detection and amplification, kit
formatting, biochips and arrays. In the therapeutics field, Enzo
inventions involve genetic modification and regulation, gene delivery,
immune regulation and specific therapeutic treatment regimens.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its menu of over 40,000
products serves the molecular biology, drug discovery and pathology
research markets. The Company's therapeutic division is in various
stages of clinical evaluation of its proprietary immune regulation
medicines for uveitis and Crohn's Disease and conducts pre-clinical
research on several candidate compounds aimed at producing new mineral
and organic bone, including technology that could provide therapy for
osteoporosis and fractures, among other applications. Enzo’s Clinical
Labs division provides routine and esoteric reference laboratory
services for physicians in the New York Metropolitan and New Jersey
areas. Underpinning the Company’s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses
over 230 patents worldwide, and has pending applications for over 200
more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
